Demographic and clinical characteristics of patients with incident gout included in analysis 1
| Not exposed | Exposed to 100 mg | Exposed to >100 mg | ||||
| Men n=9405 | Women n=4848 | Men n=1941 | Women n=951 | Men n=1287 | Women n=430 | |
| Age, mean (SD), years | 62.3 (14.5) | 68.5 (14.7) | 67.7 (13.8) | 76.5 (11.6) | 63.6 (13.5) | 74.5 (11.3) |
| Follow-up, years, median (Q1, Q3) | 4.1 (1.9, 6.7) | 4.1 (1.9, 6.7) | 4.4 (1.9, 7.0) | 3.7 (1.6, 6.2) | 5.0 (2.5, 7.6) | 4.1 (1.9, 6.3) |
| Education level, years | ||||||
| <9 | 2901 (30.9) | 1899 (39.2) | 742 (38.2) | 509 (53.5) | 446 (34.7) | 207 (48.1) |
| 9–12 | 4275 (45.5) | 1945 (40.1) | 803 (41.4) | 313 (32.9) | 537 (41.7) | 159 (37.0) |
| >12 | 2090 (22.2) | 932 (19.2) | 361 (18.6) | 109 (11.5) | 271 (21.1) | 56 (13.0) |
| Comorbidity index*, N(%) | ||||||
| 0 | 2254 (24.0) | 845 (17.4) | 217 (11.2)† | 20 (2.1)† | 1732 (13.4)† | 5 (1.2)† |
| 1–2 | 3517 (37.4) | 1877 (38.7) | 600 (30.9)† | 228 (24.0)† | 394 (30.6)† | 104 (24.2)† |
| 3–4 | 2666 (28.4) | 1527 (31.5) | 709 (36.5)† | 433 (45.5)† | 446 (34.7)† | 194 (45.1)† |
| ≥5 | 968 (10.3) | 599 (12.4) | 415 (21.4)† | 270 (28.4)† | 275 (21.4)† | 127 (29.5)† |
| Medication‡, N(%) | ||||||
| Anticoagulants/platelet aggregation inhibitors | 2956 (31.4) | 1630 (33.6) | 917 (47.2)† | 549 (57.7)† | 544 (42.3)† | 240 (55.8)† |
| CV drugs§ | 5032 (53.5) | 3066 (63.2) | 1515 (78.1)† | 891 (93.7)† | 971 (75.4)† | 404 (94.0)† |
| Cortisone | 854 (9.1) | 600 (12.4) | 312 (16.1)† | 217 (22.8)† | 203 (15.8)† | 88 (20.5)† |
*Based on the number of ever diagnosed comorbidities during the follow-up. Comorbidities included: hypertension, diabetes, hyperlipidaemia, obesity, renal disease, heart failure, cardiomyopathy, psoriasis, chronic obstructive pulmonary disease, alcoholism, cerebrovascular disease, atherosclerotic disease and cancer.
†p<0.05 compared with those not exposed.
‡Defined as dispensed prescription within 6 months before the end of follow-up.
§Drugs included: vasodilator drugs, anti-hypertensive drugs, diuretics, beta blockers, calcium antagonists and renin-angiotensin-aldosterone inhibitors.
CV, cardiovascular.